The contribution of 68Ga to the promotion and expansion of clinical research and routine
positron emission tomography (PET) for earlier better diagnostics and individualized …

This article reviews the development of bifunctional chelates for synthesising 68 Ga
radiopharmaceuticals. It structures the chelates into groups of macrocycles …

The positron-emitting radionuclide gallium-68 has become increasingly utilised in both
preclinical and clinical settings with positron emission tomography (PET). The synthesis of …

The production of novel radionuclides is the first step towards the development of new
effective radiopharmaceuticals, and the quality thereof directly affects the preclinical and …

Over the last several years, the use of radiometals has gained increasing relevance in
supporting the continuous development of new, complementary and more specific biological …

Abstract Gallium-68 (68 Ga) is a generator-produced radionuclide with a short half-life (t ½=
68 min) that is particularly well suited for molecular imaging by positron emission …

The worldwide utilization of 68Ga‐radionuclide for the fundamental research and clinical
applications is growing exponentially. A broad range of 68Ga‐based imaging agents has …

The cationic peptide 68Ga-NOTA-UBI-29-41 was synthesized and characterized.
Biodistribution and PET/CT examinations were performed for evaluation of its biologic …

Abstract Gallium-68 (68 Ga) has attracted increasing interest in recent years due to the
expanding clinical applications of 68 Ga-based radiopharmaceuticals (Rahbar et al., 2017) …

The construction of the 68 Ge/68 Ga generator has increased application of
radiopharmaceuticals labeled with this isotope in medicine. 68 Ga-PET is widely employed …